IMHA, or immune-mediated hemolytic anemia, is a serious condition in which a dog’s immune system mistakenly attacks and destroys its own red blood cells. It is one of the most common immune-related blood disorders in dogs, and it can become life-threatening quickly because red blood cells carry oxygen to every organ in the body. When those cells are destroyed faster than the body can replace them, the dog becomes severely anemic.
How IMHA Destroys Red Blood Cells
In a healthy dog, the immune system ignores its own red blood cells and targets only foreign invaders like bacteria or viruses. In IMHA, that system misfires. Antibodies latch onto the surface of red blood cells and essentially flag them for destruction. The body then eliminates those flagged cells in one of two ways.
In the more common form, called extravascular hemolysis, immune cells in the spleen and liver recognize the antibody-coated red blood cells and consume them. Think of it as the body’s cleanup crew removing what it wrongly believes is a threat. In more severe cases, the immune attack is aggressive enough to rupture red blood cells while they’re still circulating in the bloodstream. This is called intravascular hemolysis, and it tends to cause more dramatic symptoms like dark brown or red-tinged urine because the contents of the ruptured cells spill directly into the blood and get filtered through the kidneys.
Primary vs. Secondary IMHA
Veterinarians classify IMHA into two categories based on whether a trigger can be identified. In primary (or idiopathic) IMHA, no underlying cause is found. The immune system simply turns on the dog’s own red blood cells for reasons that remain unclear. This is the more common form.
Secondary IMHA is triggered by something identifiable. Known triggers include infections such as tick-borne diseases (babesiosis, ehrlichiosis, anaplasmosis), bacterial infections like leptospirosis, and certain drugs, particularly sulfonamide antibiotics. Cancer can also set off an immune response that leads to red blood cell destruction. Some limited evidence suggests a seasonal pattern, with more cases appearing in summer, and a possible temporal link between vaccination and onset, though no specific vaccine has been implicated. The thinking is that vaccines may amplify an immune process already quietly underway.
Breeds at Higher Risk
Any dog can develop IMHA, but certain breeds appear genetically predisposed. Cocker Spaniels (both American and English), English Springer Spaniels, and Clumber Spaniels have been identified as higher-risk breeds and are the focus of ongoing genetics research at the University of Minnesota. Middle-aged female dogs are also diagnosed more frequently, though the condition occurs across all ages and sexes.
Recognizing the Symptoms
IMHA often comes on fast. Within a day or two, a previously normal dog can become visibly weak, lethargic, and uninterested in food. The hallmark signs relate to the loss of red blood cells and the buildup of their breakdown products:
- Pale or yellow gums. Healthy gums are pink. In IMHA, they may turn white from anemia or develop a yellow or orange tinge from jaundice as the body struggles to process the debris from destroyed red blood cells.
- Yellowing of the whites of the eyes. This jaundice, also called icterus, is one of the more noticeable signs.
- Dark urine. Urine may appear dark orange, brown, or even reddish, especially in cases of intravascular hemolysis where ruptured cell contents are filtering through the kidneys.
- Fever. Some dogs develop an elevated temperature as the immune system ramps up.
- Rapid breathing or elevated heart rate. With fewer red blood cells carrying oxygen, the heart and lungs work harder to compensate.
These symptoms can look similar to other conditions, so lab work is essential to confirm what’s happening.
How Veterinarians Diagnose IMHA
There is no single test that definitively confirms IMHA. Instead, veterinarians look for a combination of findings: the dog is anemic, there is evidence of red blood cell destruction, and that destruction appears to be immune-driven.
One of the first clues comes from a blood smear examined under a microscope. Dogs with IMHA often have large numbers of spherocytes, which are abnormally small, round red blood cells created when immune cells in the spleen partially destroy a red blood cell without finishing the job. Seeing many spherocytes is highly suggestive of IMHA.
A slide agglutination test is another quick in-clinic check. A drop of the dog’s blood is mixed with saline on a glass slide. If the red blood cells clump together and stay clumped even after adding more saline, it indicates that antibodies on the cell surfaces are binding them to each other. This “autoagglutination” is a strong indicator of immune-mediated destruction, though a negative result doesn’t rule IMHA out since clumping only occurs when antibody levels are high.
A Coombs’ test can detect antibodies on red blood cell surfaces even when levels aren’t high enough to cause visible clumping. Blood work will also reveal signs of accelerated destruction, such as elevated bilirubin (the yellow pigment from broken-down red blood cells) and free hemoglobin in the blood or urine. Vets will also look for underlying triggers like infections or cancer to determine whether the IMHA is primary or secondary.
Treatment and What to Expect
The cornerstone of IMHA treatment is suppressing the immune system to stop it from destroying red blood cells. Corticosteroids like prednisone are the first-line medication. Dogs under about 55 pounds typically start at a weight-based dose, while larger dogs are dosed based on body surface area because they tend to experience more severe side effects like muscle wasting at higher doses.
Most dogs also receive a second immunosuppressive drug alongside steroids. Options include cyclosporine, mycophenolate, azathioprine, or leflunomide. The specific choice depends on the dog’s size, other health issues, and how the vet weighs the side-effect profiles of each drug.
Dogs with dangerously low red blood cell counts often need blood transfusions to keep their organs oxygenated while the medications take effect. Hospitalization ranges from several days to a full week in the most severe cases. During this time, red blood cell levels (measured as the packed cell volume, or PCV) are checked at least once daily to track whether the anemia is stabilizing, worsening, or improving.
Blood clots are one of the most dangerous complications of IMHA. Dogs with this condition are in a hypercoagulable state, meaning their blood clots too easily. Clots most commonly lodge in the lungs (pulmonary thromboembolism) but can also form in the liver, spleen, kidneys, or major veins. Ironically, corticosteroids themselves can increase clotting risk, though the benefit of stopping red blood cell destruction generally outweighs this concern. Many vets prescribe anti-clotting medications alongside immune suppression to reduce this risk.
Survival Rates and the Critical First Two Weeks
IMHA carries a significant mortality rate. Across seven published reviews, the average survival rate at hospital discharge was 57%, at 30 days it was 58%, and at one year it dropped to 34%. However, treatment protocols that include both immunosuppressive therapy and anti-clotting measures have shown better outcomes in some studies, with one-year survival reaching 64% to 69% depending on the combination used.
The first two weeks are the most dangerous period. Dogs that survive this initial phase have good long-term survival rates. During the first month after discharge, PCV levels need to be checked at least weekly to make sure red blood cell counts are recovering and the immune attack isn’t ramping back up.
Relapse and Long-Term Outlook
Even after successful treatment, IMHA can return. Relapse rates range from 13% to 33%, which is why immunosuppressive medications are tapered very gradually over weeks to months rather than stopped abruptly. Pulling back too quickly can trigger the immune system to resume its attack on red blood cells.
Long-term monitoring typically involves periodic blood work to catch early signs of relapse before the dog becomes symptomatic again. Some dogs remain on low doses of immunosuppressive medication for months or even indefinitely. The side effects of long-term steroid use, including increased thirst, urination, appetite, and potential weight gain, are a trade-off that most owners find manageable compared to the alternative.
Dogs with secondary IMHA generally have a better outlook if the underlying trigger (an infection, a medication, a tumor) can be identified and addressed. Removing the trigger reduces the chance the immune system will be provoked again. Dogs with primary IMHA, where no trigger is found, tend to face a somewhat higher risk of relapse since there’s nothing specific to treat beyond the immune response itself.